Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
| ▸ | TYMP | P19971 | 1/20 | 0.31 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | NCF1 | P14598 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2658021 | 0.92 | CYP3A4 (0.33) | HTT | |
| SCHEMBL1700787 | 0.86 | NR1H2 (0.33) | NR1H2 | |
| SCHEMBL624078 | 0.86 | NR1H2 (0.33) | NR1H2 | |
| SCHEMBL1700411 | 0.86 | NR1H2 (0.33) | NR1H2 | |
| SCHEMBL3634568 | 0.84 | TYMP (0.35) | HTTTYMP | |
| SCHEMBL1374035 | 0.84 | HTR2C (0.30) | ALOX5TYMPNR1H2HTR2C | |
| SCHEMBL22661275 | 0.82 | HTT (0.34) | HTTNCF1 | |
| SCHEMBL2558150 | 0.80 | AKR1C3 (0.35) | — | |
| SCHEMBL14102866 | 0.80 | HTT (0.33) | HTTNCF1 | |
| SCHEMBL15531375 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 258 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037328-B2 | Compounds containing benzo[d][1,3]oxathiole, benzo[d][1,3]oxathiole 3-oxide or benzo[d][1,3]oxathiole 3,3-dioxide and methods/uses thereof as agonists of G protein-coupled receptor 119 | PRAMANA PHARMACEUTICALS INC. (CA) | 2024-07-16 | — | — | US | disclosed |
| US-12037328-B2 | Compounds containing benzo[d][1,3]oxathiole, benzo[d][1,3]oxathiole 3-oxide or benzo[d][1,3]oxathiole 3,3-dioxide and methods/uses thereof as agonists of G protein-coupled receptor 119 | PRAMANA PHARMACEUTICALS INC. (CA) | 2024-07-16 | — | — | US | disclosed |
| US-12037328-B2 | Compounds containing benzo[d][1,3]oxathiole, benzo[d][1,3]oxathiole 3-oxide or benzo[d][1,3]oxathiole 3,3-dioxide and methods/uses thereof as agonists of G protein-coupled receptor 119 | PRAMANA PHARMACEUTICALS INC. (CA) | 2024-07-16 | — | — | US | disclosed |
| EP-4395549-A1 | COMPOSITIONS AND METHODS FOR TARGETED DEGRADATION OF PROTEINS IN A PLANT CELL | Oerth Bio LLC (US) | 2024-07-10 | — | — | EP | disclosed |
| US-20240067640-A1 | PHENYL MALEIMIDE LINKER AGENTS | FIREFLY BIO, INC. | 2024-02-29 | — | — | US | disclosed |
| WO-2024044748-A2 | PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER | WAKE FOREST UNIVERSITY HEALTH SCIENCES (US) | 2024-02-29 | — | — | WO | disclosed |
| US-11820781-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | NURIX THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| WO-2023220640-A1 | CDK PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| EP-4255573-A1 | SUBSTITUTED THIADIAZOLYL DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS | Ideaya Biosciences, Inc. (US) | 2023-10-11 | — | — | EP | disclosed |
| EP-3468967-B1 | COMPOUNDS CONTAINING BENZO[D][1,3]OXATHIOLE, BENZO[D][1,3]OXATHIOLE 3-OXIDE OR BENZO[D][1,3]OXATHIOLE 3,3-DIOXIDE AND METHODS/USES THEREOF AS AGONISTS OF G PROTEIN-COUPLED RECEPTOR 119 | PRAMANA PHARMACEUTICALS INC (CA) | 2023-07-26 | — | — | EP | disclosed |
| EP-1781664-A1 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | Methylgene, Inc. (CA) | 2007-05-09 | — | — | EP | disclosed |
| US-20070049555-A1 | Indenoisoquinolinone analogs and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2007-03-01 | — | — | US | disclosed |
| WO-2006010264-A1 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | METHYLGENE, INC. (CA) | 2006-02-02 | — | — | WO | disclosed |
| EP-1549278-A4 | M sb 3 /sb MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LTD (GB) | 2005-12-14 | — | — | EP | disclosed |
| EP-1558609-A2 | KINASE INHIBITORS | Merck & Co., Inc. (US) | 2005-08-03 | — | — | EP | disclosed |
| EP-1549278-A2 | M sb 3 /sb MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2005-07-06 | — | — | EP | disclosed |
| EP-1474420-A1 | QUINAZOLINE COMPOUNDS | Astrazeneca AB (SE) | 2004-11-10 | — | — | EP | disclosed |
| WO-2004041164-A2 | KINASE INHIBITORS | MERCK & CO., INC. (US) | 2004-05-21 | — | — | WO | disclosed |
| WO-2004012684-A2 | M3MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2004-02-12 | — | — | WO | disclosed |
| WO-2003064413-A1 | QUINAZOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2003-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049555-A1 | Indenoisoquinolinone analogs and methods of use thereof | TNNI3, IDH2, GLS | HTT 2878/4885ALOX5 119/4885TYMP 1718/4885 |
| US-11820781-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | BTK, CBL, XIAP | HTT 689/4885ALOX5 3969/4885TYMP 1999/4885 |
| US-20240067640-A1 | PHENYL MALEIMIDE LINKER AGENTS | TPX2, H1-4, MAPT | HTT 2102/4885ALOX5 4840/4885TYMP 396/4885 |
| US-12037328-B2 | Compounds containing benzo[d][1,3]oxathiole, benzo[d][1,3]oxathiole 3-oxide or benzo[d][1,3]oxathiole 3,3-dioxide and methods/uses thereof as agonists of G protein-coupled receptor 119 | GPR119, GPR3, GPR39 | HTT 3197/4885ALOX5 766/4885TYMP 4566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.